secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2026-08-05T20:07:39+00:00
Accession:  0001809519-26-000151
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q2 revenue $200.4M, Pharma Direct +76% YoY; raises FY2026 guidance
-------------------------------------------------------------------------

- Revenue $200.4M; net income $8.5M (4.3% margin); adjusted EBITDA $63.7M (31.8% margin).
- Pharma Direct revenue up 76% YoY; Subscription revenue up 39% YoY.
- Company raises full-year 2026 revenue and adjusted EBITDA expectations.
- Adjusted net income $26.8M (13.4% margin); net cash from operations $80.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/0001809519-26-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/gdrx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001809519-26-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer